The DNA replication licensing factor MCM7 is part of the MCM-complex which ensures that DNA undergoes a single round of replication per cell cycle, see [3]. It has also been shown to unwind double-stranded DNA at the replication forks, see [4]. The MCM7 gene has been shown to be up-regulated in a number of cancers compared to normal tissue. Of special interest is that the gene has been shown to be overexpressed in prostate cancer compared with the normal prostate, and this overexpression has been associated with prostate cancer progression, see [5]. This relation of overexpression and progression has also been shown for bladder cancer, see [6]. SiRNA mediated knockdown of the MCM7 gene in bladder cancer cell lines has been shown to diminish proliferation, see [7].
This APP can be used for quantifying the nuclear expression of MCM7. The approach used here to calculate expression, have in a recent study by Fristrup et al, see [8] been shown to be highly prognostic in both a test cohort (n = 283) and a validation cohort (n = 576) of non-muscle invasive bladder cancer with long-term follow-up. The MCM7 APP was in the study shown to prognosticate patients very similar to manual scoring of the protein.